Skip to search formSkip to main contentSkip to account menu

Anti-OX40 Monoclonal Antibody MEDI0562

Known as: MEDI-0562, MEDI0562 
An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, anti-OX40… 
National Institutes of Health

Related topics

Related topics

5 relations
Antibody-Dependent Cellular CytotoxicityB-LymphocytesCytotoxic T-LymphocytesNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
3003Background: We report safety and tolerability of MEDI0562, a humanized IgG1κ OX40 monoclonal antibody (mAb), in combination… 
2017
2017
A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult…
TPS3100Background: Recent advances in treatment of solid tumors include single or combined use of monoclonal antibodies (mAbs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)